TG Therapeutics Plans Cut-Price Challenger To Ocrevus In MS
Filing Expected In Q3
TG Therapeutics is confident its late-stage candidate can take a slice of the multiple sclerosis market away from Roche’s blockbuster.
You may also be interested in...
Janssen is the latest big pharma company to gain an approval for a new oral multiple sclerosis therapy in the EU, enhancing the competitiveness of the marketplace, and giving more choice for patients.
After multiple failed attempts to treat rare conditions, Marinus is on the cusp of success with ganaxolone in genetic epilepsy, and has secured a new European partner in Orion.
Has AstraZeneca been able to maintain its R&D productivity, even during a pandemic, and with the huge task of delivering a not-for-profit COVID-19 vaccine to the world?AstraZeneca’s Mene Pangalos believes the company has not missed a beat, and can find new energy from finally working together in its new R&D headquarters.